Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration

• Status: Completed
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to compare the effectiveness of reactive focal drug administration (RFDA) using dihydroartemisinin+piperaquine (DHAP) versus reactive focal test and treat (RFTAT) using artemether+lumefantrine (AL) as a routine process for identifying and eliminating malaria transmission as measured through achieving zero seropositivity in children under five in Southern Province, Zambia. These two strategies are potential candidates for expanded malaria operational surveillance and elimination for low malaria transmission areas.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: PATH
• Collaborators: AKROS Global Health; Ministry of Health, Zambia
• Treatments: Dihydroartemisinin; Piperaquine

Criteria

Inclusion Criteria:

• anyone not excluded and consenting

Exclusion Criteria:

• contraindications from manufacturer for medications including currently taking haloperidol, artane, Phenergan (Promethazine), chlorpromazine, erythromycin, Azithromycin, clarithromycin, Ketoconazole, fluconazole, mefloquine (as prophylaxis), lumefantrine (in Coartem), quinine, Septrin

• anyone seriously ill

• currently taking antimalarial medicines

• allergy to artemisinin drugs

• pregnant women in first trimester

• children under 3 months of age

• reported heart condition